Company Overview and News
Midstream and MLPs had their best day in a few months on Monday (AMZ +2.2%). They struggled to hold those gains the rest of the week, but did finish +1.8% vs. last week, in line with the utilities. Utilities followed a different path to +1.8%, selling off early in the week and rallying to close out the week. With interest rates shooting higher, price action for both midstream and utilities action went against traditional expectations, while the S&P 500 (-1%) and REITs (-3% this week) experienced a more conventional selloff.
TRP DCP NBL WLKP IPL GBNXF KMI TRP KMR PBA CVB IPPLF KMRFZ BPMP
HOUSTON, Oct. 05, 2018 (GLOBE NEWSWIRE) -- TransCanada Corporation (TSX: TRP) (NYSE: TRP) (TransCanada) today announced it has placed the Western Build of its WB XPress (WBX) project into service.
Previously a booming market, the Canadian energy sector has not witnessed any major milestones since the past few years. Industry downturn coupled with U.S. shale revolution hit the country hard, nullifying years of expansionary phase within Canada’s energy industry. With the cancellation of major projects like Northern Gateway, Pacific NorthWest and Energy East along with uncertainties relating to the existing ones, things have been quite dispiriting for investors in the Canadian oil energy space.
TRP RDS.B RDS.A RDSB RDSA KMI CSBR TRP RYDBF FLR RYDAF KMR CVB KMRFZ
2018-09-26 seekingalpha - 1
Over time, the US and Canadian energy markets have become more integrated. Energy trade and cross-border asset ownership are just some examples of this interconnectedness. Enbridge's (NYSE:ENB) simplification plan, which includes acquiring its sponsored MLPs Spectra Energy Partners (NYSE:SEP) and Enbridge Energy Partners (NYSE:EEP), is a company-level example of the overlap between US and Canadian midstream.
TRP DTK ENB ALJ KEY IPL SEP ENB ALDW KEY TRP EEP PBA IPPLF
Bringing in pleasant news for TransCanada Corporation (TRP - Free Report) , the U.S. State Department has finally green-lighted the company’s controversial Keystone XL project. Just a month back, a U.S. federal judge, Brian Morris, issued a decree requiring the State Department to conduct a fresh environmental evaluation of the Keystone XL pipeline under the new alternative route. The judge believed that the alternative route proposed by the Nebraska Public Utilities Commission had not been properly assessed.
TRP ATP AT TRP RGCO APRWF
Another up and down week in midstream, but this time midstream corporations were up and MLPs were down, although the move was small in both directions. Midstream outperformed utilities, which sold off on higher interest rates. The S&P 500 beat both midstream and utilities.
AltaGas has been consistently investing in U.S. projects over Canadian ones. Recent divestitures to fund the U.S. based WGL Holdings acquisition have tilted Canadian.
SOJA DUKH SO TRP SCG WGL DTK DUK ENB ENB ATGFF EQT WMB TRP ED PBA
Oil production is surging in North America but producers are far from happy as their profit margin is sinking. They are struggling to stay competitive owing to the infrastructural bottlenecks. As if the pipeline pinch problem was not enough for the United States and Canada, raging protests against the already approved and existing pipeline projects have made things worse.
DCUB SOJA DCUA DCUD DCUC CY UGI WGL ENB SJIU EQM KMI DRUA TRP EBBNF PAA ED KMR CVB NEE SO ENBBF DUKH TRP SJI D NJR DUK RGCO ENB ETP KMRFZ GJP
CALGARY, Alberta, 11 sept. 2018 (GLOBE NEWSWIRE) -- Communiqué de presse – Karl Johannson, président et vice-président directeur, énergie et pipelines de gaz naturel au Canada et au Mexique, TransCanada Corporation (TSX:TRP) (NYSE:TRP) (TransCanada), fera une présentation à la 22e Energy Conference annuelle de Peters & Co. Limited à Toronto, le 12 septembre 2018.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TSX:TRP / Transcanada Corp. on message board site Silicon Investor.